contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lipidor-signs-agreement-for-clinical-phase-iii-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lipidor

STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug ...

<div class="mfn-preamble"><p><strong>STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor hopes to be able to present study results already in December of the same year.</strong></p></div><div class="mfn-body"><p>During the spring and summer, AKP02G2, the modified formulation of AKP02, underwent careful internal and external evaluation. The results have been very promising, and the properties of the new formulation mean that it can be expected to provide a stronger therapeutic effect compared to its predecessor AKP02.</p><p>At the beginning of the summer, the Swedish Medicines Agency made the assessment that AKP02G2 can be used directly in a new clinical phase III study, after which the planning work for such a study was intensified. The design of the study is based on experiences from the previous phase III study for AKP02, and Lipidor has chosen to collaborate with Cliantha Research, which is a reputable CRO (Clinical Research Organization) with solid experience in dermatological research.</p><p>"We are very pleased to be able to carry out the study together with Cliantha Research, which has previously conducted a large number of similar phase III studies, and has also received excellent references from our own network," says Lipidor's CEO Ola Holmlund.</p><p>In addition to selecting a CRO, the planning work for the clinical study has also included a process to select and start work with a manufacturer of clinical trial material (CMO). For CMO, Lipidor has chosen Medfiles Oy in Finland, which has initiated preparations for production of the clinical trial material so that this can be available by the start of the study.</p><p>"I am convinced that with the help of Cliantha Research's clinical experience and Medfiles's commitment to the clinical trial material, we can carry out this study efficiently and with high quality," says Dr. Vibhu Rinwa, program manager at Lipidor.</p><p>A prerequisite for the phase III study to be carried out according to plan is that Lipidor is to have new funding in place.</p><p><strong>Publication</strong></p><p>The information was provided for publication by&nbsp;Lipidor’s&nbsp;CEO on&nbsp;20 September 2023&nbsp;at 2.55pm (CEST).</p></div><div class="mfn-footer mfn-contacts mfn-ec2f69be0eda"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><p>Ola Holmlund, CEO<br>Telephone: +46 (0) 72 50 70 369<br>Email: <a rel="noopener" href="mailto:ola.holmlund@lipidor.se">ola.holmlund@lipidor.se</a></p><p>The company´s Certified Adviser is Erik Penser Bank AB.</p></div><div class="mfn-footer mfn-about mfn-e061b566de55"><p><strong class="mfn-heading-1">About Lipidor AB</strong><br>Lipidor AB (Nasdaq First North Growth Market: LIPI) (<a rel="noopener" href="http://www.lipidor.se">www.lipidor.se</a>) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of&nbsp;proven&nbsp;pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/817c27ab-ace6-474d-bdad-443e34fb7d22/lipidor-signs-agreement-for-clinical-phase-iii-study.pdf" class="mfn-generated mfn-primary">Lipidor signs agreement for clinical phase III study</a></p></div>

Lipidor signs agreement for clinical phase III study

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa

USA:n työllisyysluvut: Taapertaen kohti vuoden loppua